Scarica l'app Stockscreener
748.87
2.47%
-18.98
Dopo l'orario di chiusura:
749.36
0.49
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$767.85
Aprire:
$771.48
Volume 24 ore:
751.19K
Relative Volume:
1.01
Capitalizzazione di mercato:
$79.17B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
18.02
EPS:
41.5626
Flusso di cassa netto:
$3.77B
1 W Prestazione:
-1.70%
1M Prestazione:
-3.00%
6M Prestazione:
+32.63%
1 anno Prestazione:
+37.06%
Intervallo 1D:
$739.09
$771.48
Intervallo di 1 settimana:
$739.09
$775.62
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal - The Motley Fool Australia
Telix and Regeneron Announce Strategic Radiopharma Collaboration - PR Newswire
Jim Cramer on Regeneron (REGN): “I Think The Stock’s Breaking Out Here” - Insider Monkey
Robeco Institutional Asset Management Boosts Regeneron Pharmaceuticals Stake - National Today
Robeco Institutional Asset Management B.V. Purchases 140,966 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Investors May Respond To Regeneron (REGN) Extending EYLEA HD Dosing Intervals To 20 Weeks - simplywall.st
Should FDA Approval of Extended EYLEA HD Dosing Flexibility Require Action From Regeneron Pharmaceuticals (REGN) Investors? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. $REGN Stake Raised by Bar Harbor Wealth Management - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Today's Analyst Rating Update for Regeneron Pharmaceuticals (REG - GuruFocus
Morgan Stanley Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Piper Sandler reiterates Overweight rating on Regeneron stock at $875 - Investing.com
Regeneron Pharmaceuticals Inc stock: What you should know now - AD HOC NEWS
Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart.com
Intratumoral Cancer Therapies Market: Expanding Revenue - openPR.com
DDD Partners LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline - GlobeNewswire Inc.
Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Aug Final Week: Does Regeneron Pharmaceuticals Inc have pricing power2026 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn
OFI Invest Asset Management Buys Regeneron Pharmaceuticals Shares - National Today
OFI Invest Asset Management Buys Shares of 31,265 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC - MarketBeat
Regeneron (REGN) Faces $102M Charge Impacting Q1 2026 Earnings - GuruFocus
Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Analyst Lowers Price Target for REGN, Maintains Outperform Ratin - GuruFocus
Sanford C. Bernstein Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Bernstein SocGen lowers Regeneron stock price target on revenue mix shift - Investing.com Australia
COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene - Barchart.com
Regeneron Pharmaceuticals, Inc. Form 8-K Filing Details for April 8, 2026 – Company Info, Stock, and Compliance 2324 - Minichart
Regeneron expects $102 million IPR&D charge to impact Q1 2026 earnings - Investing.com Australia
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $921 - Moomoo
Raymond James reiterates Outperform on Regeneron stock on Eylea HD growth - Investing.com
Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - marketbeat.com
Avoiding Lag: Real-Time Signals in (REGN) Movement - Stock Traders Daily
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Raises Target Price to $779 - Moomoo
Eosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, Pfizer - Barchart.com
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $765, Maintains Sector Perform Rating - Moomoo
Monoclonal Antibody Therapeutics (Mabs) Market (2026-2033) | - openPR.com
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals - simplywall.st
Regeneron And TriNetX Partner To Expand Global Genomic And EHR Linked Data Platform - BioPharma APAC
Surprises Report: What are the future prospects of Regeneron Pharmaceuticals IncWeekly Market Outlook & Smart Swing Trading Techniques - baoquankhu1.vn
Targets Report: Is Regeneron Pharmaceuticals Inc gaining market shareQuarterly Earnings Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval - Yahoo Finance
FDA approves expanded EYLEA HD dosing intervals - Eyes On Eyecare
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy - Yahoo Finance
Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC - MarketBeat
2,145 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Perpetual Ltd - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):